Harbin Pharmaceutical Group's low P/S ratio may indicate anticipated poor growth or falling revenue, underperforming the industry. The company's recent revenue trends, worse than industry expectations, contribute to its low P/S. Shareholders accept this, expecting no future revenue surprises. Unless medium-term conditions improve, they will continue to hinder the share price.

Low P/S ratio suggests investors think company's growth may not keep up with the industry. Recent revenue trends imply the share price may not rise soon. Investors should beware of a specific warning for the company.

Market might be less excited about Harbin Pharmaceutical Group hinting at a possible buying opportunity. The company's five-year annualised TSR loss signals caution for potential investors.